Psychiatr. praxi. 2014;15(1):6-8

Treatment of hospitalized patients with schizophrenia

prof.MUDr.Eva Češková, CSc., MUDr.Michaela Mayerová
CEITEC-MU, Psychiatrická klinika LF MU a FN Brno

The most frequent reasons for hospitalization in patients suffering from schizophrenia are relapses and pharmacoresistancy. The main

cause of relapse is nonadherence which can be partially managed by depot antipsychotics. The gold standard of treatment in pharmacoresistant

patients is clozapine. In spite of this clozapine is initiated late in clinical practice and before initiating clozapine, antipsychotic

polypharmacy is very common. After the failure of clozapine monotherapy there are several possibilities including combination

of clozapine with other antipsychotics and clozapine augmentation. There are very few controlled studies supporting these strategies

with inconsistent results; therefore the pseudoresistance should be eliminated. The optimal possibility includes clozapine plasma levels

assessment. The results obtained at department of psychiatry in Brno show, that in patients non-responding to clozapine its plasma

levels are surprisingly often out of the therapeutic range. The clozapine plasma levels assessment in these problematic patients helps

to choose the further optimal treatment strategy.

Keywords: schizophrenia, relaps, pharmacoresistance, combinatins of antipsychotics, clozapine, plasma levels

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E, Mayerová M. Treatment of hospitalized patients with schizophrenia. Psychiatr. praxi. 2014;15(1):6-8.
Download citation

References

  1. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Medical Care 2002; 40: 630-639. Go to original source... Go to PubMed...
  2. Češková E. Schizofrenie a její léčba, 3. vydání, 117 stran. Maxdorf Jessenius, Praha, 2012.
  3. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, et al. WFSBP Task Force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 2012; 13: 318-378. Go to original source... Go to PubMed...
  4. Hasan A, Falkai P, Wobrock T, et al. WFSBP Task force on Treatment Guidelines for Schizophrenia. Word Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological treatment of Schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013; 14: 2-44. Go to original source... Go to PubMed...
  5. Glazer WM. The depot paradox. Behav Health 2007; 27: 44-46.
  6. Tattan TMG, Creed FH. Negative symptoms of schizophrenia and compliance with medication. Schizophr Bull 2001; 27: 149-155. Go to original source... Go to PubMed...
  7. Češková E, Přikryl R, Péč O. Schizofrenie dospělého věku. V: Psychiatrie. Doporučené postupy psychiatrické péče III (ed. Raboch J, Anders M, Kellerova P, Uhlíková P), Tribun EU, 2010: 115-123.
  8. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012; 201: 481-485. Go to original source... Go to PubMed...
  9. Barnes TR, Paton C. Antipsychotic polypharmacy in schizophrenia: benefits and risks. CNS Drugs 2011; 25: 383-399. Go to original source... Go to PubMed...
  10. Češková E, Kašpárek T, Ondrušová M. Kombinace antipsychotik. Č.S. Psychiat 2001; 97: 286-290.
  11. Sušilová L, Češková E. Monoterapie a kombinace antipsychotik u pacientů hospitalizovaných s diagnózou schizofrenie ve FN Brno. Čes a slov Psychiatr 2013; 109: 122-127.
  12. Češková E, Švestka J, Náhunek K, et al. Experience with the reduction of maintenance doses of clozapine and monitoring of its blood levels. Activ Nerv Super 1989; 31: 118-119.
  13. Češková E. Plazmatické hladiny klozapinu. Č.S. Psychiatr 1995; 91: 234-240.
  14. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265. Go to original source... Go to PubMed...
  15. Hiemke C, Baumann P, Bergemann N, et al. AGAP Consensus Guidelines for Therapeutic Drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235. Go to original source... Go to PubMed...
  16. Češková E. Zlepší monitorování krevních hladin adherenci a efekt léčby u schizofrenie? Psychiatr praxi 2011; 12: 166-168.
  17. Češková E, Vrzalová M. Optimalizace farmakoterapie schizofrenní poruchy. Psychiatr praxi 2012; 13: 156-159.
  18. Vrzalová M, Češková E, Pivnička J, Přikryl R, Ustohal L, Přikrylová H, Kašpárek T. Brněnské zkušenosti s monitorováním plazmatických hladin clozapinu (CLO) a olanzapinu (OLA). Psychiatrie 2013; 17(suppl. 1): 35.




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.